Fannie Mae, Freddie Mac shares tumble after conservatorship comments
ROCKAWAY, NJ—John P. Gandolfo, a director at electroCore, Inc. (NASDAQ:ECOR), has increased his stake in the company through a recent purchase of common stock. According to a Form 4 filing with the Securities and Exchange Commission, Gandolfo acquired 1,800 shares on May 23, 2025, at a price of $5.01 per share, totaling $9,018. The purchase comes as the stock trades significantly below its 52-week high of $19.49, with analysts setting price targets between $12 and $25. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value estimate.
Following this transaction, Gandolfo’s direct ownership in electroCore stands at 69,087 shares. This figure includes 59,493 shares vested from previously issued Deferred Stock Units (DSUs) and 5,528 shares that are scheduled to vest monthly through September 3, 2025. These DSUs will vest fully on the earlier of either the day before the company’s next annual stockholder meeting or the date immediately preceding a change of control, contingent on Gandolfo’s continued service with the company. The micro-cap company, valued at $36.88 million, maintains a strong balance sheet with more cash than debt, though InvestingPro data shows it’s currently unprofitable with negative EBITDA of $11.43 million in the last twelve months. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis for ECOR through the Pro Research Report.
In other recent news, ElectroCore reported a 23% increase in revenue for Q1 2025, totaling $6.7 million. Despite this growth, the company faced a net loss of $3.9 million, or $0.47 per share, and experienced a reduction in cash reserves from $12.2 million to $8 million. ElectroCore’s gross margin improved slightly to 85%, up from 84% the previous year. The company has projected full-year 2025 revenue of approximately $30 million, with a goal of achieving cash neutrality by the end of 2025 or early 2026. ElectroCore recently completed the acquisition of the Quell product line from Neurometrics, aiming to enhance its presence in the bioelectronic health and wellness sector. The company also announced a distribution agreement with Spark Biomedical to offer the Sparrow Ascent product line for opioid withdrawal treatment. These strategic moves are expected to support ElectroCore’s growth and diversification efforts in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.